HR 6963
Pediatric Cancer Drug Supply Act of 2024
Take action
Record your position on this measure.
Sign in to record your position, submit testimony, or contact your legislator.
Sign in to take action- Introduced
- Passed House
- Passed Senate
- To President
- Became Law
Bill overview
The Pediatric Cancer Drug Supply Act of 2024 aims to ensure a stable supply of critical medications used to treat pediatric cancer. It establishes a pilot program where the Department of Health and Human Services will partner with drug manufacturers to maintain a 6-month reserve supply of designated ‘essential’ pediatric cancer drugs. The bill also creates a list of these essential drugs and outlines procedures for distributing them during shortages, while providing potential incentives for manufacturers to increase domestic production capacity.
Sponsors
Official sponsors from legislative records.
Primary sponsor
Anna G. Eshoo
Cosponsors
Ann M. Kuster
David J. Trone
Arguments in favor
Reasons to support this legislation.
No arguments in favor have been submitted.
Submit yoursArguments opposed
Reasons to oppose this legislation.
No arguments opposed have been submitted.
Submit yoursRead the latest version inline or switch to a previous version.